GlassScriptPhysician profile
David S Reid
NPI 1497755805
$3,447.02
in general payments reported to CMS, 2019-2025
20 companies · $1,169 in 2025
The $1,169 reported for 2025 was more than what 76% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $354 · 2021: $528 · 2022: $405 · 2023: $146 · 2024: $427 · 2025: $1,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,028 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $714.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,008.02 | 2023-2025 | |
| Musculoskeletal Transplant Foundation INC. | $491.49 | 2020-2025 | |
| Merz North America, INC. | $468.12 | 2021-2025 | |
| Mentor Worldwide LLC | $424.56 | 2019-2024 | Mentor Memorygel Resterilizable Gel Sizer |
| Allergan, INC. | $358.41 | 2019-2022 | |
| Exelixis INC. | $129.40 | 2019 | |
| Genzyme Corporation | $98.03 | 2019 | |
| Tela Bio, INC. | $90.67 | 2023-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Endo Pharmaceuticals INC. | $85.00 | 2020-2023 | Xiaflex |
| Janssen Biotech, INC. | $72.18 | 2019 | |
| Integra Lifesciences Corporation | $38.85 | 2022 | |
| Endo USA, INC. | $33.29 | 2024 | Xiaflex |
| Hydrocision, INC. | $25.84 | 2022 | |
| Organogenesis INC. | $23.73 | 2022 | |
| Galderma Laboratories, L.P. | $23.23 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $20.34 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $16.64 | 2022 | |
| Genentech USA, INC. | $14.93 | 2022 | |
| Sientra, INC. | $12.77 | 2020 | |
| Acelrx Pharmaceuticals, INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.